Microcap Ledger Camp4 Therapeutics Corp $CAMP
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Global Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Watertown, MA
- Fiscal year end
- December 31
- Shares outstanding
- 62,753,200 [10-Q 2026-08-13]
What the company doesAI summary of filing
Camp4 Therapeutics is a clinical-stage biopharmaceutical company developing antisense oligonucleotide therapeutics targeting regulatory RNAs to upregulate gene expression for genetic diseases. The company's lead program, CMP-002, is designed to treat SYNGAP1-related developmental and epileptic encephalopathy by increasing SYNGAP1 protein levels; the company is initiating GLP toxicology studies with plans for a Phase 1/2 clinical trial as early as the second half of 2026. The company also has CMP-001 for urea cycle disorders, which completed a Phase 1 trial in healthy volunteers, and is leveraging a collaboration with GlaxoSmithKline to extend its proprietary RAP Platform technology platform beyond the central nervous system. Camp4 is pre-revenue and funded through upfront payments, milestone payments, and royalties from its GSK partnership. [10-K 2026-03-05]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $3.07M | −$51.86M | −$23.67M | $86.40M | [10-Q 2026-08-13] |
| FY ended Dec 2025 | $3.50M | −$80.40M | −$29.55M | $109.52M | [10-K 2026-03-05] |
| FY ended Dec 2024 | $652.0K | −$51.79M | −$45.56M | $64.04M | [10-K 2026-03-05] |
- Quarterly cash burn
- −$11.83M
- Cash runway Estimate
- ~21.9 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-18 | 20,161,073 | [10-Q 2024-11-21] |
| 2025-03-13 | 20,161,072 | [10-K 2025-03-27] |
| 2025-05-06 | 20,161,073 | [10-Q 2025-05-13] |
| 2025-08-05 | 20,161,073 | [10-Q 2025-08-14] |
| 2025-11-03 | 46,881,134 | [10-Q 2025-11-06] |
| 2026-03-04 | 51,919,321 | [10-K 2026-03-05] |
| 2026-05-06 | 51,925,800 | [10-Q 2026-05-07] |
| 2026-08-12 | 62,753,200 | [10-Q 2026-08-13] |
- Shelf registration
- S-3 filed 2026-08-06; declared effective 2026-08-12 [S-3 2026-08-06]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-08-31 | Gold Kelly | buy | 10,000 | $3.96 | [4 2026-09-02] |
| 2026-08-27 | Schwab Andrew J. | sell | 400,000 | $4.04 | [4 2026-08-31] |
| 2026-08-24 | Schwab Andrew J. | sell | 10 | $4.50 | [4 2026-08-26] |
| 2026-08-21 | Schwab Andrew J. | sell | 32,018 | $4.50 | [4 2026-08-21] |
| 2026-08-20 | Schwab Andrew J. | sell | 114,700 | $4.54 | [4 2026-08-21] |
| 2026-08-19 | Schwab Andrew J. | sell | 45,147 | $4.76 | [4 2026-08-21] |
| 2026-08-19 | Tardiff Daniel | sell | 1,738 | $4.76 | [4 2026-08-19] |
| 2026-08-03 | Young Richard A | buy | 16,378 | $1.65 | [4 2026-08-05] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-28 | 8-K | Regulation FD disclosure; Other events |
| 2026-08-31 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-08-19 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-13 | 10-Q | Quarterly report |
| 2026-08-13 | 8-K | Results of operations |
| 2026-08-12 | 424B3 | Prospectus or prospectus supplement |
| 2026-08-10 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-06 | S-3 | Registration statement |
| 2026-08-05 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-08-04 | 8-K | Material agreement entered; Unregistered sale of equity; Regulation FD disclosure |
| 2026-07-27 | 8-K | Regulation FD disclosure; Other events |
Alerts for $CAMP
Email me when Camp4 Therapeutics Corp files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.